Endometrial Cancer Patient Biomarkers and Survival Outcomes, 232 Patients

232 surgical endometrial cancer patients from January 2021 to October 2022 were analyzed for progression-free and overall survival. The dataset includes serum levels of HE4, CEA, and CA125, as well as MMP9 and MMP13 gene polymorphisms, used to develop predictive nomograms. It was authored by Renliang Li and shared under a CC-BY-4.0 license.

Use Cases

• Predicting 3-year progression-free survival based on serum HE4 levels and tumor stage.
• Analyzing the association between MMP9 R279Q polymorphisms and patient survival outcomes.
• Developing a clinical nomogram integrating biomarkers, stage, and grade for risk stratification.
• Comparing the prognostic value of serum biomarkers (HE4, CEA, CA125) against genetic polymorphisms.

Strengths

• Includes data from 232 patients with clear temporal coverage (Jan 2021–Oct 2022).
• Nomogram models achieved high predictive accuracy (AUC of 0.935 for PFS and 0.914 for OS).
• Analysis includes multiple biomarker types: serum protein levels and SNP genotyping for MMP9/MMP13.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal and clinical bias inherent to the single-cohort, retrospective study design.

Provenance

Source

figshare, author Renliang Li

Collection Method

Retrospective cohort study of surgical patients.

Time Range

January 2021 to October 2022

Freshness

Last updated 2026-04-25 11:48:05; freshness should be verified.